Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

Eupraxia’s CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

Treatment options available for patients ... 1 720 777 7457 Fax: +1 720 777 7277 [email protected]. Eosinophilic esophagitis (EoE) presents with a constellation of symptoms including feeding ...

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. On April 24, 2025, Eupraxia Pharmaceuticals announced its participation in several ...

Cedars-Sinai researchers have developed a novel nutritional formula, mBiota Elemental, a palatable elemental diet (PED) that ...

Apogee Therapeutics, Inc.’s APGE share price has surged by 5.14%, which has investors questioning if this is right time to ...

Eosinophilic esophagitis (EoE) is a chronic esophageal ... must be made on both clinical and histological grounds. Effective treatments rely on steroids and dietary exclusions.

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

Eupraxia Pharmaceuticals Inc.’s EPRX share price has surged by 5.46%, which has investors questioning if this is right time ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

In a US study, patients with severe eosinophilic esophagitis (EoE) by Index of Severity for EoE had poor responses to topical corticosteroid therapy.